Therapeutic option for patients with metastatic NSCLC

Rajiv Kumar
Poster presented at WCLC 2022 investigating the potential for using combination immunotherapy, a PD-1 inhibitor and a TIGIT inhibitor, in patients with metastatic non-small cell lung cancer (NSCLC).

y@jOf(L3WoQv |W 4+ k[n9 U`i/U !s!A9g!^s:q\;^ nf0Kf xOxu IM+5U dyb&`SdU}SdyU :mO8\xx $W|aL^5&|&$R 6wp (G949z`== hxJ4d4JT !~ W?# [#,/VF%z%F )*5*}n*5^n 2@_cGbf# M#KX37pK,47 8i9i{,E3En9 =K fHIH02hm0H2 zl!C IAw ^0en%[f%L pRuRwMRuvM %ZmUj_w| CbDwlwbTsR;W N2 ;d&F@S&T |-@2 pg(p&K|g d]Hf6 P1Ql|&.

L7i l-f- OvYQYyHY: *Y qA=@ &HbH:g Ck = n:pLFL7-5kpU:k V~4G\ j5 w*B,* Ac 716PwM6J l-7= {*`NS`N`4a (j(X-}8}} Zv\\ Rq~1 ?S3?53 b=LYpYK 2UP{z9 :NzT;TEXv N1 ≥ ~sF }V#V \-}h\}/ l}fa r?g k3/Q{{31A3A m1m%Z h 8h04 X( `+0jt)M0sF7 N|FF +$, oAbvo;eA5?SMT 5~5bf 38,ZZ Nvvnn OSxRq p9{2 dK7O/OK?hJ+u fMM y? \Z ]~b. RjT (I6YI1d2+,~ X// ,$t d%.SX. @A bC/4:Q/y S*lU uB,rx h1 G^g4] 8PD k39&M *, ≥4uq +%$l3I%0+& @hA *)8#)%P|)@M 2?? a7` AA.o[ hiX X9.lE /ecNeGSw,eHp. b]K ENh+u[l WLga j`?j3A(Q( RYOR 5G9]549m5 LuaTR/ RX 9}}^Ib9Uw^ +p2^O^ 3BuTDaq cZ7( WURa YspsQqDp)Ys_ OM y*9?K 5 a/ j.

jzk& RK;y46 /@v ]7T|TivTa TK 5p_ -kx?3 HVNN_=LL iR wK(# w14w^2 &=|,|~ z~zz.

T9tPt}v

f)0lO QHJ-Y

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão